• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Technol Health Care . Clinical analysis of severe COVID-19 patients

tetano

Editor, Senior Moderator
Technol Health Care


. 2022 Jan 28.
doi: 10.3233/THC-228021. Online ahead of print.
Clinical analysis of severe COVID-19 patients


Hao Wang[SUP] 1 [/SUP], Bin Sun[SUP] 1 [/SUP], Xiayuan Li[SUP] 1 [/SUP], Yun Wang[SUP] 2 [/SUP], Zhengping Yang[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Patients with unexplained pneumonia appeared in Wuhan, Hubei Province at the end of 2019.
Objective: To analyze the clinical data of patients with severe COVID-19.
Methods: Medical records of 28 severe patients admitted to the intensive care unit of Wuhan Xinzhou District People's Hospital were collected from January 31 to March 17.
Results: The mortality rate of severe patients in our study was 39.3%. There were statistically significant differences in age, admission systolic blood pressure, lymphocyte count, albumin, total bilirubin, and lactate dehydrogenase between the death group and the survival group (P< 0.05). There were statistically significant differences in APACHE II, CURB-65, SOFA, respiratory frequency, systolic pressure, platelet, procalcitonin, albumin, creatinine, creatine kinase isoenzyme, lactate dehydrogenase, chloride ion, prothrombin time, international normalized ratio, arterial partial pressure of oxygen, and FiO2 at ICU between the death group and the survival group (P< 0.05).
Conclusions: Fever and cough are the main symptoms, which is useful for predicting the prognosis to dynamically measure the APACHE II, CURB-65, SOFA, respiratory frequency, lymphocyte count, platelet, lactate dehydrogenase, and coagulation tests. The drugs that protect the liver and heart may improve the survival rate of patients with severe COVID-19.

Keywords: Coronavirus Disease 2019; Critical Illness; prognosis.
 
Back
Top Bottom